Production of antibodies with peptide-CpG-DNA-liposome complex without carriers

BMC Immunology

Volumn 12, Issue , 2011, Pages

  Kim, Dongbum ^a   Kwon, Sanghoon ^a   Rhee, Jae W ^a   Kim, Kwang D ^b   Kim, Young Eun ^c   Park, Cheung Seog ^d   Choi, Myeong J ^e   Suh, Jun Gyo ^a   Kim, Doo Sik ^f   Lee, Younghee ^c   Kwon, Hyung Joo ^a  

^a Hallym University   (South Korea)

^b Gyeongsang National University   (South Korea)

^c Chungbuk National University   (South Korea)

^d Kyung Hee University Hospital   (South Korea)

^e Korea Clinical Research Center Cp Ltd   (South Korea)

^f Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CANCER VACCINE; CYTOKINE; DNA; EPITOPE; FLUORESCEIN ISOTHIOCYANATE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPLEX; LIPOSOME; MONOCLONAL ANTIBODY; OVALBUMIN; PEPTIDE; TOLL LIKE RECEPTOR 9; TUMOR ANTIGEN; VACCINE; ALCAM PROTEIN, HUMAN; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; FETOPROTEIN; IMMUNOGLOBULIN G; LEUKOCYTE ANTIGEN; NERVE CELL ADHESION MOLECULE; OLIGODEOXYRIBONUCLEOTIDE; PEPTIDE FRAGMENT;

ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; CANCER CELL; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; INFECTION; INFLUENZA; LIVER CELL CARCINOMA; MALARIA; MOUSE; NEOPLASM; NONHUMAN; PEPTIDE SYNTHESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; SPLEEN CELL; VACCINE PRODUCTION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; EPITOPE MAPPING; GENETICS; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOUSE MUTANT; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CELL ADHESION MOLECULES, NEURONAL; CELL LINE, TUMOR; EPITOPE MAPPING; FETAL PROTEINS; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; OLIGODEOXYRIBONUCLEOTIDES; PEPTIDE FRAGMENTS; TOLL-LIKE RECEPTOR 9;

EID: 79955972217     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-12-29     Document Type: Article

References (45)

1. Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y, Furutani Y, Yano O, Kataoka T, Sudo T, Makiguchi N, Suganuma T. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 1984, 72:955-962.
2. Messina JP, Gilkeson GS, Pisetsky DS. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol 1991, 147:1759-1764.
3. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549. 10.1038/374546a0, 7700380.
4. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996, 157:1840-1845.
5. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997, 186:1623-1631. 10.1084/jem.186.10.1623, 2199137, 9362523.
6. Carson DA, Raz E. Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J Exp Med 1997, 186:1621-1622. 10.1084/jem.186.10.1621, 2199144, 9411016.
7. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM. CpG-DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998, 160:870-876.
8. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760. 10.1146/annurev.immunol.20.100301.064842, 11861616.
9. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5:471-484. 10.1038/nrd2059, 16763660.
10. Stein CA, Subasinghe C, Shinozuka K, Cohen JS. Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 1988, 16:3209-3221. 10.1093/nar/16.8.3209, 336489, 2836790.
11. Zhao Q, Waldschmidt T, Fisher E, Herrera CJ, Krieg AM. Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors. Blood 1994, 84:3660-3666.
12. Gursel I, Gursel M, Ishii KJ, Klinman DM. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 2001, 167:3324-3328.
13. Li WM, Dragowska WH, Bally MB, Schutze-Redelmeier MP. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 2003, 21:3319-3329. 10.1016/S0264-410X(03)00172-5, 12804863.
14. Suzuki Y, Wakita D, Chamoto K, Narita Y, Tsuji T, Takeshima T, Gyobu H, Kawarada Y, Kondo S, Akira S, Katoh H, Ikeda H, Nishimura T. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res 2004, 64:8754-8760. 10.1158/0008-5472.CAN-04-1691, 15574787.
15. Sparwasser T, Hultner L, Koch ES, Luz A, Lipford GB, Wagner H. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J Immunol 1999, 162:2368-2374.
16. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, Zinkernagel R, Aguzzi A. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004, 10:187-192. 10.1038/nm987, 14745443.
17. Deng GM, Nilsson IM, Verdrengh M, Collins LV, Tarkowski A. Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med 1999, 5:702-705. 10.1038/9554, 10371511.
18. Kim D, Rhee JW, Kwon S, Sohn WJ, Lee Y, Kim DW, Kim DS, Kwon HJ. Immunostimulation and anti-DNA antibody production by backbone modified CpG-DNA. Biochem Biophys Res Commun 2009, 379:362-367. 10.1016/j.bbrc.2008.12.063, 19103173.
19. Liang H, Nishioka Y, Reich CF, Pisetsky DS, Lipsky PE. Activation of human B cells by phosphorothioate oligodeoxynucleotides. J Clin Invest 1996, 98:1119-1129. 10.1172/JCI118894, 507533, 8787674.
20. Yasuda K, Yu P, Kirschning CJ, Schlatter B, Schmitz F, Heit A, Bauer S, Hochrein H, Wagner H. Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways. J Immunol 2005, 174:6129-6136.
21. Magnusson M, Tobes R, Sancho J, Pareja E. Natural DNA repetitive extragenic sequences from Gram-negative pathogens strongly stimulate TLR9. J Immunol 2007, 179:31-35.
22. Lee KW, Jung J, Lee Y, Kim TY, Choi SY, Park J, Kim DS, Kwon HJ. Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA. Mol Immunol 2006, 43:2107-2118. 10.1016/j.molimm.2005.12.004, 16442622.
23. Lee SA, Lee SY, Cho IH, Oh MA, Kang ES, Kim YB, Seo WD, Choi S, Nam JO, Tamamori-Adachi M, Kitajima S, Ye SK, Kim S, Hwang YJ, Kim IS, Park KH, Lee JW. Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma. J Clin Invest 2008, 118:1354-1366. 10.1172/JCI33768, 2268877, 18357344.
24. Hacker H, Mischak H, Miethke T, Liptay S, Schmid R, Sparwasser T, Heeg K, Lipford GB, Wagner H. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J 1998, 17:6230-6240. 10.1093/emboj/17.21.6230, 1170949, 9799232.
25. Agrawal S, Kandimalla ER. Medicinal chemistry and therapeutic potential of CpG-DNA. Trends Mol Med 2002, 8:114-121. 10.1016/S1471-4914(01)02264-X, 11879771.
26. Lee KW, Kim DS, Kwon HJ. CG sequence- and phosphorothioate backbone modification-dependent activation of the NF-κB-responsive gene expression by CpG-oligodeoxynucleotides in human RPMI 8226 B cells. Mol Immunol 2004, 41:955-964.
27. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745. 10.1038/35047123, 11130078.
28. Ben-Yedidia T, Arnon R. Design of peptide and polypeptide vaccines. Curr Opin Biotechnol 1997, 8:442-448. 10.1016/S0958-1669(97)80066-3, 9265723.
29. Ben-Yedidia T, Arnon R. Epitope-based vaccine against influenza. Expert Rev Vaccines 2007, 6:939-948. 10.1586/14760584.6.6.939, 18034655.
30. Bijker MS, Melief CJ, Offringa R, van der Burg SH. Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines 2007, 6:591-603. 10.1586/14760584.6.4.591, 17669012.
31. Chikh G, Schutze-Redelmeier MP. Liposomal delivery of CTL epitopes to dendritic cells. Biosci Rep 2002, 22:339-353. 10.1023/A:1020151025412, 12428909.
32. Felnerova D, Viret JF, Gluck R, Moser C. Liposomes and virosomes as delivery system for antigens, nucleic acids and drugs. Curr Opin Biotechnol 2004, 15:518-529. 10.1016/j.copbio.2004.10.005, 15560978.
33. Simoes S, Moreira JN, Fonseca C, Duzgunes N, de Lima MC. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev 2004, 56:947-965. 10.1016/j.addr.2003.10.038, 15066754.
34. Ben-Yedidia T, Marcus H, Reisner Y, Arnon R. Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection. Int Immunol 1999, 11:1043-1051. 10.1093/intimm/11.7.1043, 10383936.
35. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC, Murphy BR. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 1994, 68:5321-5325. 236482, 8035532.
36. Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 1996, 70:2852-2860. 190142, 8627759.
37. Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R, Sattentau QJ, Openshaw PJ. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 2006, 12:905-907. 10.1038/nm1456, 16862151.
38. Gregoriadis G, Saffie R, Hart SL. High yield incorporation of plasmid DNA within liposomes: Effect on DNA integrity and transfection efficiency. J Drug Target 1996, 3:469-475. 10.3109/10611869609015966, 8863139.
39. Roberts TL, Dunn JA, Terry TD, Jennings MP, Hume DA, Sweet MJ, Stacey KJ. Differences in macrophage activation by bacterial DNA and CpG-containing oligonucleotides. J Immunol 2005, 175:3569-3576.
40. Parker JM, Hodges PC. New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and x-ray-derived accessible sites. Biochemistry 1986, 25:5425-5432. 10.1021/bi00367a013, 2430611.
41. Emini EA, Hughes JV, Perlow DS, Boger J. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol 1985, 55:836-839. 255070, 2991600.
42. Chou PY, Fasman GD. Prediction of the secondary structure of proteins from their amino acid sequence. Adv Enzymol Relat Areas Mol Biol 1978, 47:45-148.
43. Kolaskar AS, Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett 1990, 276:172-174. 10.1016/0014-5793(90)80535-Q, 1702393.
44. Yokoyama WM, Christensen M, Santos GD, Miller D. Production of monoclonal antibodies. Curr Protoc Immunol 2006, Chapter 2(Unit 2.5).
45. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988, 48:589-601.